Complete financial analysis of Yunkang Group Limited (2325.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Yunkang Group Limited, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Heritage NOLA Bancorp, Inc. (HRGG) Income Statement Analysis – Financial Results
- SHIKHAR LEASING & TRADING LTD. (SHIKHARLETR.BO) Income Statement Analysis – Financial Results
- Lobe Sciences Ltd. (LOBEF) Income Statement Analysis – Financial Results
- XCPCNL Business Services Corporation (XCPL) Income Statement Analysis – Financial Results
- Sparebanken Vest (SVEG.OL) Income Statement Analysis – Financial Results
Yunkang Group Limited (2325.HK)
About Yunkang Group Limited
Yunkang Group Limited operates as a medical operation service provider in the People's Republic of China. The company offers diagnostic testing services for medical institution alliances, including setting up or upgrading diagnostic centers, the establishment of standard operating procedures for diagnostic testing, diagnostic consultation and staff training, procurement of equipment, smart internet of things, and logistics assistance. It also provides diagnostic outsourcing services comprising pathology tests; infectious disease diagnostic tests, including hepatitis B virus, tuberculosis, human papilloma virus, EB virus, rabies virus, and nucleic acid tests for respiratory pathogens; genetic reproduction and screening tests; and routine diagnostic tests for chronic kidney, blood, autoimmune, endocrine metabolism, and other diseases. In addition, the company offers diagnostic testing services for financial institutions and insurance companies, including personalized diagnostic testing, medical report consultation, and hospital referral services; information technology, medical logistics, and medical equipment procurement; healthcare technology development; and project investment. It provides its services through independent clinical laboratories and on-site diagnostic centers. Yunkang Group Limited was founded in 2008 and is headquartered in Guangzhou, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 891.50M | 4.37B | 2.04B | 1.35B | 676.98M | 619.71M |
| Cost of Revenue | 565.71M | 2.90B | 978.50M | 622.71M | 387.67M | 380.23M |
| Gross Profit | 325.79M | 1.47B | 1.07B | 726.08M | 289.32M | 239.48M |
| Gross Profit Ratio | 36.54% | 33.58% | 52.15% | 53.83% | 42.74% | 38.64% |
| Research & Development | 0.00 | 51.10M | 52.96M | 37.49M | 36.43M | 39.73M |
| General & Administrative | 191.64M | 386.67M | 152.08M | 56.68M | 0.00 | 0.00 |
| Selling & Marketing | 150.86M | 312.01M | 273.30M | 219.02M | 0.00 | 0.00 |
| SG&A | 342.49M | 925.47M | 470.31M | 321.35M | 265.46M | 253.22M |
| Other Expenses | 35.87M | -1.19M | -455.00K | -114.00K | 0.00 | 0.00 |
| Operating Expenses | 378.36M | 976.57M | 523.27M | 358.84M | 301.90M | 292.95M |
| Cost & Expenses | 944.08M | 3.88B | 1.50B | 981.56M | 689.56M | 673.18M |
| Interest Income | 9.33M | 5.18M | 10.75M | 2.12M | 1.05M | 18.60M |
| Interest Expense | 43.56M | 19.85M | 17.23M | 19.20M | 11.38M | 5.45M |
| Depreciation & Amortization | 68.32M | 181.46M | 67.30M | 44.94M | 33.00M | 30.13M |
| EBITDA | 25.07M | 619.32M | 524.28M | 382.02M | 31.12M | 1.48M |
| EBITDA Ratio | 2.81% | 15.37% | 29.85% | 30.56% | 3.02% | -3.77% |
| Operating Income | -52.58M | 490.07M | 543.17M | 367.24M | -12.58M | -53.47M |
| Operating Income Ratio | -5.90% | 11.22% | 26.56% | 27.23% | -1.86% | -8.63% |
| Total Other Income/Expenses | -34.24M | 57.10M | 86.12M | -18.63M | 3.22M | -4.65M |
| Income Before Tax | -86.81M | 515.65M | 543.82M | 364.51M | -8.66M | -33.33M |
| Income Before Tax Ratio | -9.74% | 11.81% | 26.59% | 27.03% | -1.28% | -5.38% |
| Income Tax Expense | 15.08M | 80.79M | 94.88M | 59.02M | 756.06K | -3.96M |
| Net Income | -102.26M | 377.31M | 380.93M | 255.33M | -30.92M | -51.35M |
| Net Income Ratio | -11.47% | 8.64% | 18.63% | 18.93% | -4.57% | -8.29% |
| EPS | -0.17 | 0.72 | 0.75 | 0.47 | -0.05 | -0.08 |
| EPS Diluted | -0.17 | 0.72 | 0.75 | 0.47 | -0.05 | -0.08 |
| Weighted Avg Shares Out | 611.14M | 613.19M | 613.19M | 613.19M | 613.19M | 613.19M |
| Weighted Avg Shares Out (Dil) | 611.14M | 613.19M | 613.19M | 613.19M | 613.19M | 613.19M |
Source: https://incomestatements.info
Category: Stock Reports